论文部分内容阅读
目的观察胸腺肽α1联合NP方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效及对免疫功能、毒副作用的影响。方法随机选择符合标准的NSCLC64例,分为治疗组和对照组各32例,治疗组使用胸腺肽α1联合NP方案化疗,对照组仅用NP方案化疗,观察两组患者的总有效率、疾病进展时间、细胞免疫功能及毒副反应。结果治疗组细胞免疫功能及对血液的毒副反应与对照组相比,差异有统计学意义(P<0.05),而临床疗效、疾病进展时间、非血液学毒性反应比较,组间差异无统计学意义(P>0.05)。结论胸腺肽α1联合NP方案治疗晚期NSCLC能提高机体的免疫功能,是一安全、有效的治疗方法。
Objective To observe the clinical efficacy of thymosin α1 combined with NP regimen in the treatment of advanced non-small cell lung cancer (NSCLC) and its effects on immune function and side effects. Methods Sixty-four NSCLC patients were randomly divided into treatment group (32 cases) and control group (n = 32). Thymosin α1 combined with NP regimen was used in the treatment group and NP regimen was used in the control group. The total effective rate, disease progression time , Cellular immune function and toxicity. Results Compared with the control group, the cellular immune function and the side effects on the blood in the treatment group were significantly different (P <0.05). However, there was no statistical difference between the two groups in clinical efficacy, disease progression time and non-hematologic toxicity Significance (P> 0.05). Conclusion Thymosin α1 combined with NP regimen in the treatment of advanced NSCLC can improve the immune function of the body, which is a safe and effective treatment.